Entries |
Document | Title | Date |
20080200523 | Derivatives of squaric acid with anti-proliferative activity - The present invention provides derivatives of squaric acid, in particular derivatives of 3,4-diamino-cyclobut-3-ene-1,2-dione and tautomers and isomers thereof, as a single stereoisomer or a mixture of stereoisomers, or as a pharmaceutically acceptable salt thereof. These compounds show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer. | 08-21-2008 |
20080214625 | Roflumilast for the Treatment of Diabetes Mellitus - The invention relates to the use of Roflumilast and/or Roflumilast N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast N-Oxide with other active agents for the treatment of diabetes mellitus. | 09-04-2008 |
20080221171 | Phenylaminopyridines - The invention relates to novel substituted 3-phenylamino-5-(3-aminophenyl)pyridines and corresponding pyrazines of formula (I), wherein A is CH, C-lower alkyl or N, R | 09-11-2008 |
20080234333 | Novel Hydroxamic Acid Derivative as Peptide Deformylase Inhibitor and Manufacturing Method Thereof - The present invention relates to the novel antibacterial compounds having potent antibacterial activity as inhibitors of peptide deformylase. This invention further relates to pharmaceutically acceptable salts thereof, to processes for their preparation, and to pharmaceutical compositions containing them as an active ingredient. | 09-25-2008 |
20080234334 | 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS - This invention is directed to compounds of formula I, | 09-25-2008 |
20080255209 | Combination of a NSAID and a PDE-4 inhibitor - The invention relates to the combined use of a PDE4 inhibitor and a conventional NSAID in the treatment of an inflammatory disease and/or an inflammation-associated disorder while minimizing gastrointestinal side effects, such as gastric erosions and ulcer, which are frequently associated with the use of conventional NSAIDs. A preferred PDE 4 inhibitor for this combination is roflumilast or a derivative thereof. A preferred conventional NSAID for this combination is diclofenac or a derivative thereof. | 10-16-2008 |
20080280958 | Topically applicable pharmaceutical preparation - A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form. | 11-13-2008 |
20080306123 | NOVEL COMPOUNDS - A compound of Formula (I) | 12-11-2008 |
20080312293 | 2-Arylpropionic Acid Derivatives and Pharmaceutical Compositions Containing Them - The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion. | 12-18-2008 |
20080312294 | Tricyclic Compounds, Compositions, and Methods - The present invention is directed to compounds of Formula I: | 12-18-2008 |
20090012129 | NOVEL BIAROMATIC COMPOUNDS THAT MODULATE PPAR-RECEPTORS - Novel biaromatic compounds that modulate peroxisome proliferator-activator receptors, known as PPAR, having the formula (I): | 01-08-2009 |
20090042951 | Blood Pressure Reduction in Salt-Sensitive Hypertension - This invention provides methods and compositions, most preferably pharmaceutical compositions, for treating salt-sensitive hypertension through the inhibition of certain enzymes in the beta-adrenergic pathway that are involved in the regulation of the secretion of water and sodium. These enzymes are cyclic nucleotide phosphodiesterases (PDE) that selectively hydrolyze the second messenger cAMP and, therefore, down-regulate beta-adrenergic signaling. Specifically provided are methods and pharmaceutical compositions for treating salt-sensitive hypertension by inhibiting certain members of the PDE4 family of cyclic nucleotide phosphodiesterases, particularly members of the PDE4B and PDE4D sub-families and, more particularly, the PDE4B1 and PDE4D5 isotypes thereof. | 02-12-2009 |
20090062351 | Benzoyl amino pyridyl carboxylic acid derivatives useful as glucokinase (glk) activators - A compound of Formula (I): Formula (I) wherein: R | 03-05-2009 |
20090082408 | NOVEL HETEROCYCLIC DERIVATIVES - The present invention relates to novel heterocyclic derivatives of the general formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The present invention more particularly provides novel compounds of the general formula (I). | 03-26-2009 |
20090131487 | GROWTH FACTOR-BINDING COMPOUNDS AND METHODS OF USE - Growth factor binding compounds having a plurality of acyclic isophthalic acid groups attached to a non-peptide organic scaffold and pharmaceutical compositions of the same are disclosed. Methods of administering and using the growth factor binding compounds or the growth factor binding compositions are also taught. These novel growth factor binding compounds are useful for treating angiogenesis, excessive cellular proliferation, tumor growth, and a combination thereof as well as inhibiting growth factor binding to cells and phosphorylation. | 05-21-2009 |
20090163557 | Cannabinergic Lipid Ligands - One aspect of this disclosure relates generally to lipid compounds that exert diverse effects in the endocannabinoid system, such as regulating CB1 and CB2 receptor or moderating other bio-macromolecules within the endocannabinoid system. Some of the compounds showed improved receptor binding affinity, and/or improved receptor subtype selectivity, and improved bio-stability. Some of the compounds exhibit activities to regulate the enzymes that moderate the bio-disposal of endogenous cannabinoids, such as the fatty acid amide hydrolase (FAAH). Some of the compounds exhibit activities to inhibit the anandamide transporter. Other aspects of the invention are pharmaceutical preparations employing these ligands and methods of administering therapeutically effective amounts of the preparations to provide a physiological effect. | 06-25-2009 |
20090182016 | OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS - The present invention discloses optically pure (R) and (S) Phenyramidol enantiomers and their pharmaceutically acceptable salts, a process for synthesising such enantiomers by means of a styrene oxide based asymmetric synthesis, and also a clinical evaluation of (R) and (S) enantiomers of Phenyramidol, their salts and compositions thereof for enhanced/newer therapeutic benefits. | 07-16-2009 |
20090209599 | Eye drop containing roflumilast - An object of the present invention is to enhance the efficacy of roflumilast in an eye drop containing roflumilast as an active ingredient. By formulating at least one type of viscosity-increasing agent in the eye drop containing roflumilast as an active ingredient, an eye drop in which the efficacy of roflumilast is enhanced can be prepared. | 08-20-2009 |
20090215836 | Roflumilast for the Treatment of Pulmonary Hypertension - The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension. | 08-27-2009 |
20090264478 | SULFASALAZINE FORMULATIONS IN A BIODEGRADABLE POLYMER CARRIER - Effective treatments of acute pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulfasalazine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 10-22-2009 |
20090281148 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND METHODS - The present invention is directed to compounds of Formula I: | 11-12-2009 |
20090306149 | USE OF BIARYLCARBOXAMIES IN THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS - The invention provides methods for modulating, e.g., antagonizing, the activity of the Hedgehog signaling pathway. In particular, the invention provides methods for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, Hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a compound of the invention (e.g., a compound of Formula I). | 12-10-2009 |
20090306150 | CARBOXYLIC ACID SALTS OF 2-AMINO-3-CARBETHOXYAMINO-6-(4-FLUORO-BENZYLAMINO)-PYRIDINE - The preparation of flupirtine carboxylate acid addition salts having the following formula (2), | 12-10-2009 |
20090318506 | Sulfonate salts of 2-amino-3-carbethoxyamino-6-(4-fluoro-benzylamino)-pyridine - Flupirtine acid addition salts having the following formula (2), | 12-24-2009 |
20100004295 | Hydrazine amide derivative - Disclosed is a novel compound having an NPY Y5 receptor antagonistic activity. | 01-07-2010 |
20100035937 | SOLUBILIZED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS - A process for producing a solubilized non-steroidal anti-inflammatory drug (NSAID) the process comprising the steps of: providing a mixture comprising solid NSAID and a first base which is selected from the group of bases which have a pH of at least 11 as 0.1 molar aqueous solution or dispersion, and reacting the NSAID and the first base in essentially dry state, solubilized NSAID obtainable by this process and pharmaceutical compositions comprising the same. | 02-11-2010 |
20100056584 | NOVEL 2-AMINIO-PYRIDINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS - This invention relates to novel 2-amino-pyridine derivative useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 03-04-2010 |
20100063113 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR - The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. | 03-11-2010 |
20100069443 | COMPOUND WITH BENZAMIDE SKELETON HAVING CYCLOOXYGENASE-1 (COX-1)-SELECTIVE INHIBITORY ACTIVITY - This invention provides a novel COX-1-selective inhibitor. This invention relates to a novel compound represented by the formula below or a salt thereof. This invention also relates to an analgesic agent, an antiinflammatory agent, an antitumor agent, an antiplatelet aggregation agent, and a cyclooxygenase-1-selective inhibitor comprising, as an active ingredient, such compound or salt thereof. | 03-18-2010 |
20100069444 | PHENATHRENONE COMPOUNDS, COMPOSITONS AND METHODS - The present invention is directed to compounds of Formula I: | 03-18-2010 |
20100144799 | OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS - The present invention discloses optically pure (R) and (S) Phenyramidol enantiomers and their pharmaceutically acceptable salts, a process for synthesizing such enantiomers by means of a styrene oxide based synthesis, and also a clinical evaluation of (R) and (S) enantiomers of Phenyramidol, their salts and compositions thereof for enhanced/newer therapeutic benefits. | 06-10-2010 |
20100152253 | NON-STEROIDAL BRASSINOSTEROID MIMETIC - The present invention relates to non-steroidal mimetics of brassinosteroids. More specifically, it relates to non-steroidal monocyclic compounds, capable of rescuing the brassinosteroid receptor null mutation bri1-116. Preferably, said compounds are low molecular weight, monocyclic halogenated compound. | 06-17-2010 |
20100160391 | Substituted Aminopyridines as Fluorescent Reporters for Amide Hydrolases - The present invention provides conjugates comprising a substituted aminopyridine covalently attached to an organic molecule via an amide bond. Such conjugates find utility as substrates for amide hydrolases, where the substituted aminopyridine acts as a fluorescent reporter of amide hydrolase activity. As a result, the conjugates described herein can advantageously be used in assays to detect amide hydrolase activity based upon measuring the fluorescence of a substituted aminopyridine that is released after amide hydrolysis. The conjugates of the present invention are also particularly useful in screening assays, which enable the identification of inhibitory molecules for amide hydrolases and other enzymes. The identified amide hydrolase inhibitors can be used in the treatment of a variety of diseases and disorders associated with aberrant amide hydrolase activity. | 06-24-2010 |
20100210693 | BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention is directed to compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. | 08-19-2010 |
20100240711 | SOLID PREPARATION COMPRISING NPYY5 RECEPTOR ANTAGONIST - A preparation which can improve solubility of a NPYY5 receptor antagonist in water, even when the NPYY5 receptor antagonist is contained in the preparation at a high content is provided. A solid preparation containing a NPYY5 receptor antagonist, an amorphous stabilizer, and optionally an amorphousization inducing agent. Particularly, when the amorphous stabilizer is hydroxypropylmethylcellulose phthalate and/or hydroxypropylmethylcellulose acetate succinate, and the amorphousization inducing agent is urea and/or saccharine sodium at an addition amount of less than 8% by weight, dissolution out property of a water-hardly soluble NPYY5 receptor antagonist could be improved. | 09-23-2010 |
20100280081 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS - The present invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, | 11-04-2010 |
20100286214 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND METHODS - The present invention is directed to compounds of Formula I: | 11-11-2010 |
20100324098 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 12-23-2010 |
20100324099 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 12-23-2010 |
20100324100 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 12-23-2010 |
20100331376 | Process for Recovering Flunixin From Pharmaceutical Compositions - This invention is generally directed to a method for recovering flunixin and flunixin analogs from pharmaceutical compositions. The recovered flunixin and analogs can be, for example, reused to make new pharmaceutical compositions and thereby reduce the need and expense of manufacturing new flunixin and flunixin analogs. | 12-30-2010 |
20110003865 | NOVEL 2-DIETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS - This invention relates to novel 2-diethylamino-3-amido-6-amino-pyridine derivatives having medical utility, to use of the 2-diethylamino-3-amido-6-amino-pyridine derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2-diethylamino-3-amido-6-amino-pyridine derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to activation of K | 01-06-2011 |
20110003866 | NOVEL 2-DIMETHYLAMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS - This invention relates to novel 2-dimethylamino-3-amido-6-amino-pyridine derivatives having medical utility, to use of the 2-dimethylamino-3-amido-6-amino-pyridine derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2-dimethylamino-3-amido-6-amino-pyridine derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to activation of K | 01-06-2011 |
20110003867 | NOVEL 2-ETHYL-METHYL-AMINO-3-AMIDO-6-AMINO-PYRIDINE DERIVATIVES USEFUL AS POTASSIUM CHANNEL ACTIVATORS - This invention relates to novel 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives having medical utility, to use of the 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives of the invention for the manufacture of a medicament, to pharmaceutical compositions comprising the 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives of the invention, and to methods of treating a disorder, disease or a condition of a subject, which disorder, disease or condition is responsive to activation of K | 01-06-2011 |
20110003868 | TREATMENT OF A NEUROPATHY WITH RAPID RELEASE AMINOPYRIDINE - A process for treating neuropathy includes administration to a patient suffering from a neuropathy more than 5 and less than 18 mg of aminopyridine in a dose. The aminopyridine is formulated in an immediate release formulation. At least two such doses are provided per day to create spike serum plasma levels of aminopyridine sufficient to drive the aminopyridine across the blood-nerve barrier. | 01-06-2011 |
20110021580 | PLANT DISEASE CONTROL COMPOSITION - A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect. | 01-27-2011 |
20110034521 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES - The present invention provides compounds and methods for treating zinc matrix metalloprotease dependent diseases. In certain embodiments, the compounds of the present invention have the following formulas: | 02-10-2011 |
20110034522 | METHODS FOR ALLEVIATING DELETERIOUS EFFECTS OF 3-DEOXYGLUCOSONE - Disclosed is a class of compounds which inhibit the enzymatic conversion of fructose-lysine into fructose-lysine-3-phosphate in an ATP dependent reaction in a newly discovered metabolic pathway. According to the normal functioning on this pathway, fructose-lysine-3-phosphate (FL3P) is broken down to form free lysine, inorganic phosphate and 3-deoxyglucosone (3DG), the latter being a reactive protein modifying agent. 3DG can be detoxified by reduction to 3-deoxyfructose (3DF), or it can react with endogenous proteins to form advanced glycation end-product modified proteins (AGE-proteins) Also disclosed are therapeutic methods of using such inhibitors to alleviate deleterious effects of 3DG. | 02-10-2011 |
20110060016 | Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient - Disclosed is a method of treatment of COPD by oral administration of roflumilast. | 03-10-2011 |
20110098325 | PYRIDINE BENZAMIDES AND PYRAZINE BENZAMIDES USED AS PKD INHIBITORS - The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyridine benzamide and pyrazine benzamide compounds (referred to herein as PDBA and PZBA compounds) which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc. | 04-28-2011 |
20110130429 | PYRIDINES FOR TREATING INJURED MAMMALIAN NERVE TISSUE - Embodiments of the present disclosure provide a novel pyridine, pharmaceutical compositions comprising such pyridine, and the use of such compositions in treating injured mammalian nerve tissue, including but not limited to an injured spinal cord. In at least one embodiment of the method, the method comprises the step of administering to the mammal in need thereof with a pharmaceutical composition, or pharmaceutically acceptable salt, comprising 4-aminopyridine-3-methanol. | 06-02-2011 |
20110136878 | AMIDE DERIVATIVE, PEST CONTROL AGENT CONTAINING THE AMIDE DERIVATIVE, AND PEST CONTROLLING METHOD - A pest control agent containing a compound represented by the following Formula (1), wherein A represents a carbon atom, a nitrogen atom, or the like, K represents a non-metal atom group necessary for forming a cyclic linking group derived from a 5- or 6-membered aromatic ring, in combination with A and two carbon atoms to which A bonds, X represents a hydrogen atom, a halogen atom, or the like, n represents an integer of from 0 to 4, T represents —C(=G | 06-09-2011 |
20110166187 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. | 07-07-2011 |
20110166188 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. | 07-07-2011 |
20110166189 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. | 07-07-2011 |
20110184030 | Pharmaceutically acceptable salt and polymorphic forms of flupirtine maleate - The present invention is concerned with new polymorphic forms of flupirtine maleate, processes for preparing the new polymorphic forms, pharmaceutical compositions containing them, therapeutic uses thereof and methods of treatment employing them. | 07-28-2011 |
20110184031 | G-Protein-Conjugated Receptor Agonist - Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabetes, a pancreatic beta differentiating cell growth enhancer, a therapeutic agent for metabolic syndrome, a therapeutic agent for a gastrointestinal disease, a therapeutic agent for a neuropathy, a therapeutic agent for a mental disorder, a therapeutic agent for a pulmonary disease, a therapeutic agent for a pituitary hormone secretion disorder or a lipid flavoring/seasoning agent. The aralkyl carboxylic acid compound is represented by the general formula (I). (I) wherein the ring Q represents a pyridyl or the like; R | 07-28-2011 |
20110184032 | Novel Phenylamino Isonicotinamide Compounds - The invention provides novel compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. | 07-28-2011 |
20110207783 | RENIN INHIBITORS - The present invention relates to acyclic amino amide renin inhibitor compounds and their use in treating cardiovascular events and renal insufficiency. | 08-25-2011 |
20110224266 | 4 AMINOPYRIDINE AND A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEURONAL DISORDERS - A composition is provided having the formula | 09-15-2011 |
20110251244 | Oral Dosage Form Containing A PDE 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidone As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 10-13-2011 |
20110275679 | FLUPIRTINE HYDROCHLORIDE MALEIC ACID COCRYSTAL - The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain disorders, and musculoskeletal disorders and to pharmaceutical compositions containing the cocrystal. | 11-10-2011 |
20110313005 | TOPICALLY APPLICABLE PHARMACEUTICAL PREPARATION - A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form. | 12-22-2011 |
20110319454 | DERIVATIVES OF CYCLOALKYL- AND CYCLOALKENYL-1,2-DICARBOXYLIC ACID COMPOUNDS HAVING FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) AGONIST OR ANTAGONIST ACTIVITY - The invention provides well defined compounds having FPRL-1 agonist or antagonist activity. As such, the compounds of the invention are useful for treating a variety of ocular disorders. | 12-29-2011 |
20120022116 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX - Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III): | 01-26-2012 |
20120029035 | COMPOSITIONS AND METHODS FOR EXTENDED THERAPY WITH AMINOPYRIDINES - Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis. | 02-02-2012 |
20120029036 | PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDYL CYANOGUANIDINE, PROCESS FOR PREPARING THE SAME AND USE THEREOF - Disclosed are a composition comprising a pyridyl cyanoguanidine and a cyclodextrin, a cyclodextrin derivative and/or a surfactant with solubilization, process for preparing the same and use thereof. | 02-02-2012 |
20120041034 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 02-16-2012 |
20120071519 | CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR - Provided herein are crystalline forms of a maleate salt of betrixaban, compositions and methods of preparation or use thereof. | 03-22-2012 |
20120088802 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND METHODS - The present invention is directed to compounds of Formula I: | 04-12-2012 |
20120088803 | CONTROL AGENT FOR SOFT ROT AND CONTROL METHOD FOR THE SAME - Provided is a novel control agent for soft rot and a novel control method for the same. The control agent for soft rot of a plant contains 3-chloro-N-(3-chloro-5-trifluoromethyl-2-pyridyl)-alpha,alpha,alpha-trifluoro-2,6-dinitro-p-toluidine as an active ingredient, which is applied to plant cultivation soil. | 04-12-2012 |
20120095062 | TRICYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS - The present invention is directed to compounds of Formula I: | 04-19-2012 |
20120108642 | TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I) | 05-03-2012 |
20120122934 | 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES - Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 4-(p-quinolyl)-2-hydroxybutanamide derivatives. Methods and compounds useful in treating other disorders such as amyotrophic lateral sclerosis (ALS), Huntington's disease, Parkinson's disease, and pervasive developmental disorders such as autism are also disclosed. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed. | 05-17-2012 |
20120157502 | PHENANTHRENONE COMPOUNDS, COMPOSITIONS AND METHODS - The present invention is directed to compounds of Formula I: | 06-21-2012 |
20120178783 | HDAC INHIBITORS - This invention provides the compound having the structure | 07-12-2012 |
20120220635 | AMINOETHYLAROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR - The present invention relates to aromatic compounds of the formula (I) and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D | 08-30-2012 |
20120277271 | METHODS AND COMPOSITIONS - The present invention relates generally to the field of pain management, and in particular, the management of neuropathic or inflammatory pain including a neuropathic or inflammatory component of nociceptive pain. More particularly, the present invention provides methods and compositions which treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms of neuropathic or inflammatory pain. The present invention further contemplates combination therapy involved in the treatment of pain in association with the treatment of a particular disease condition or pathology. The present invention further also provides sustained and slow release formulations, tamper-proof deliver systems and stents, catheters and other mechanical devices coated with formulations which permit sustained or slow release of active ingredients involved in pain management. | 11-01-2012 |
20130005778 | URETHANES, UREAS, AMIDINES AND RELATED INHIBITORS OF FACTOR XA - The invention relates to a new class of compounds, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions that are effective as selective inhibitors of factor Xa, both in the isolated state and in a complex with other proteins. The compounds of the invention can be used for treating and preventing diseases, such as acute coronary syndrome, myocardial infarction, unstable angina, refractory angina, thromboses caused by post-thrombolytic therapy or coronary angioplasty, acute ischemia mediated cerebrovascular syndrome, embolic stroke, thrombotic stroke, and other diseases in humans and other mammals associated with blood coagulation problems. | 01-03-2013 |
20130030025 | USE OF POTASSIUM CHANNEL BLOCKERS TO TREAT CEREBRAL PALSY - Disclosed herein is the use of aminopyridines, such as 3-aminopyridine, 4-aminopyridine or 3,4-diaminopyridine, in the management and treatment of cerebral palsy patients of all ages. | 01-31-2013 |
20130053420 | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients With Demyelinating and Other Nervous System Conditions - Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, to improve the neuro-cognitive impairments and related neuro-psychiatric impairments of patients with a demyelinating condition such as MS, traumatic brain injury, cerebral palsy, post-radiation encephalopathy. | 02-28-2013 |
20130085166 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS - The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect. | 04-04-2013 |
20130085167 | METHODS FOR TREATING A STROKE-RELATED SENSORIMOTOR IMPAIRMENT USING AMINOPYRIDINES - Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with a stroke-related impairment, in particular, in patients with a stroke-related sensorimotor impairment. | 04-04-2013 |
20130102640 | METHOD FOR THE PREPARATION OF CIS-1,2-DIOLS IN THE KILOGRAM SCALE - The present invention relates to the scale up of the preparation of cis-1,2-diols of formula I | 04-25-2013 |
20130109725 | GRANULES WITH IMPROVED DISPERSION PROPERTIES | 05-02-2013 |
20130131123 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - An immediate release solid dosage form in tablet or pellet form for oral administration of a PDE 4 inhibitor, comprising a PDE 4 inhibitor that is N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (roflumilast) or a salt thereof, and one or more suitable pharmaceutical excipients; wherein said dosage form contains 500 μg of the roflumilast or salt thereof. | 05-23-2013 |
20130143932 | OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS - The present invention discloses optically pure (R) and (S) Phenyramidol enantiomers and their pharmaceutically acceptable salts, a process for synthesizing such enantiomers by means of a styrene oxide based synthesis, and also a clinical evaluation of (R) and (S) enantiomers of Phenyramidol, their salts and compositions thereof for enhanced/newer therapeutic benefits. | 06-06-2013 |
20130150414 | PEST CONTROL AGENT - Specific amine derivatives have been found to possess excellent activities as pest control agents. | 06-13-2013 |
20130184314 | Novel Phenylamino Isonicotinamide Compounds - The invention provides novel compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer, restenosis and inflammation. | 07-18-2013 |
20130184315 | SULFONYL COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR - Compounds of formula (I) and formula (II) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 07-18-2013 |
20130184316 | METHODS FOR DIAGNOSING AND TREATING CONCUSSIVE DISORDERS - The invention provides methods for treating, suppressing, ameliorating and/or preventing the effects of disorders relating to concussion, including those associated with post-concussion syndrome. The methods comprise administering to a subject an effective amount of a compound that modulates neuronal ion channel function, or a pharmaceutically acceptable salt, solvate or hydrate thereof, or a composition comprising a compound that modulates neuronal ion channel function, or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a pharmaceutically acceptable carrier. The invention also provides inventive methods relating to identifying, classifying and/or diagnosing conditions involving post-concussion syndrome and related concussive disorders. | 07-18-2013 |
20130197040 | POLYMORPHS OF DALFAMPRIDINE, PREPARATIONS AND USES THEREOF - Provided are polymorphs I to VIII of a dalfampridine or of its solvates, a preparation method therefore, and applications thereof as an active component of a medicine. Said polymorphs Ito VIII of the dalfampridine or of its solvents can be used to prepare formulations for improving the walking speed of patients of multiple sclerosis and for alleviating other symptoms of multiple sclerosis. | 08-01-2013 |
20130210866 | METHODS FOR TREATING AN IMPAIRMENT IN GAIT AND/OR BALANCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AN AMINOPYRIDINE - Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis. | 08-15-2013 |
20130225643 | ENDOGENEOUS REPAIR FACTOR PRODUCTION ACCELERATORS - It relates to an endogenous repair factor production accelerator which comprises one or at least two selected from prostaglandin (PG) I2 agonist, EP2 agonist and EP4 agonist. Since prostaglandin (PG) I2 agonist, EP2 agonist or EP4 agonist has various endogenous repair factor production accelerating action, angiogenesis acceleration action and stem cell differentiation induction action, it is useful as preventive and/or therapeutic agents for ischemic organ diseases (e.g., arteriosclerosis obliterans, Buerger disease, Raynaud disease, myocardial infarction, angina pectoris, diabetic neuropathy, spinal canal stenosis, cerebrovascular accidents, cerebral infarction, pulmonary hypertension, bone fracture, Alzheimer disease, etc.) and various cell and organ diseases. | 08-29-2013 |
20130267566 | DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION - Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS. | 10-10-2013 |
20130289081 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE - A derivative of nicotinic acid N-oxide is described having formula (I): that acts as inhibitor of enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO), and is thus able to reduce QUIN biosynthesis in vivo under excitotoxic or pathological conditions, said compound being at the same time also chemically stable towards auto-oxidation. | 10-31-2013 |
20130310426 | SUSTAINED RELEASE AMINOPYRIDINE COMPOSITION - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 11-21-2013 |
20130345265 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 12-26-2013 |
20140018397 | Sustained Release Aminopyridine Composition - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 01-16-2014 |
20140024683 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES - The present invention provides, inter alia, methods and pharmaceutical compositions for preventing, treating, or ameliorating the effects of a disease characterized by altered smooth muscle contractility, such as e.g., asthma and chronic obstructive pulmonary disease. | 01-23-2014 |
20140031396 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP binder. | 01-30-2014 |
20140031397 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 01-30-2014 |
20140039015 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. | 02-06-2014 |
20140080875 | 3,4-DIAMINOPYRIDINE TARTRATE AND PHOSPHATE, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to 3,4-diaminopyridine salts, pharmaceutical compositions containing at least one of said salts and uses thereof for the treatment of botulism, myasthenia, myasthenic syndromes or fatigue. | 03-20-2014 |
20140194477 | KINASE PROTEIN BINDING INHIBITORS - The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer. | 07-10-2014 |
20140206728 | DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION - Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS. | 07-24-2014 |
20140221435 | AMIDES AS MODULATORS OF SODIUM CHANNELS - The invention relates to amide compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: | 08-07-2014 |
20140256775 | NOVEL TRANSCRIPTION FACTOR MODULATORS - The present disclosure provides novel compounds capable of functioning as transcription factor modulators, as well as compositions, pharmaceutical formulations, and kits. Also provided are methods of treating a condition regulatable by a transcription factor and/or cofactor using the compounds, compositions, pharmaceutical formulations, and kits provided herein. | 09-11-2014 |
20140296304 | Pharmaceutically Active Disubstituted Pyridine Derivatives - The present invention relates to disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, cardiovascular diseases, cell proliferative diseases, inflammation, erectile dysfunction and stroke, and pharmaceutical compositions containing at least one of said disubstituted pyridine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said disubstituted pyridine derivatives as inhibitors for a protein kinase. | 10-02-2014 |
20140303215 | TOPICALLY APPLICABLE PHARMACEUTICAL PREPARATION - A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form. | 10-09-2014 |
20140343107 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS - The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect. | 11-20-2014 |
20140378513 | USE OF FUNGICIDES IN LIQUID SYSTEMS - The present disclosure provides methods to detect pests in liquid culture systems for the growth of microalgae. The disclosure further provides methods to treat and control pests in a liquid system and for methods to increase yields of microalgae grown in a liquid culture systems. Methods are provided for the growth, monitoring, treatment and harvesting of microalgae from liquid culture systems. | 12-25-2014 |
20150051254 | Treatment of Cognitive Impairment With PDE4 Inhibitor - This invention relates to the treatment of varying degrees of cognitive impairment associated with, for example, aging, Alzheimer's disease, schizophrenia with low dose administration of a PDE4 inhibitor, specifically roflumilast. | 02-19-2015 |
20150080436 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition. | 03-19-2015 |
20150105433 | TREATING VIRAL INFECTIONS HAVING VIRAL RNAs TRANSLATED BY A NON-IRES MEDIATED MECHANISM - Provided herein are methods for preventing or treating a viral infection in a subject, wherein the viral infection is mediated by a virus comprising one or more viral RNA molecules translated by a ribosomal shunting mechanism or a non-IRES mediated mechanism. The methods comprise administering to a subject an agent that reduces ribosomal protein (Rps25) expression or function. Also provided are methods of inhibiting or promoting ribosomal shunting-mediated translation or non-IRES mediated translation. Also provided are methods of screening for an agent that inhibits or promotes ribosomal shunting-mediated translation or non-IRES mediated translation. | 04-16-2015 |
20150111930 | TOPICAL REGIONAL NEURO-AFFECTIVE THERAPY - A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed. | 04-23-2015 |
20150119426 | MODULATORS OF THE RELAXIN RECEPTOR 1 - Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R | 04-30-2015 |
20150141469 | KIT FOR PRODUCING FOAMS CONTAINING BISPYRIDINIUM ALKANE - A kit for the production of an antimicrobial foam includes: a) a liquid composition which includes a1)one or more bispyridinium alkane and a2)one or more surfactants selected from non-ionic surfactants, amphoteric surfactants and cation-active surfactants, wherein the composition is formulated so that a foam can be produced therefrom, and b) a device for producing the foam from the composition. By using the bispyridinium alkanes the foam stability of liquid and surfactant-containing compositions is increased. | 05-21-2015 |
20150290178 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 10-15-2015 |
20150290179 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 10-15-2015 |
20150290180 | Oral Dosage Form Containing A PDE 4 Inhibitor as an Active Ingredient and Polyvinylpyrrolidon as Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 10-15-2015 |
20150313886 | COMPOSITIONS AND METHODS FOR EXTENDED THERAPY WITH AMINOPYRIDINES - Disclosed herein are methods and compositions related to use of aminopyridines, such as 4-aminopyridine, for use in a therapeutically effective manner for patients with a demyelinating condition, such as multiple sclerosis. | 11-05-2015 |
20150328196 | AMIDES AS MODULATORS OF SODIUM CHANNELS - The invention relates to amide compounds of formula I and I′ or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: | 11-19-2015 |
20150351394 | BACTERICIDAL COMPOSITION CONTAINING FLUAZINAM - The present invention discloses a bactericidal composition containing fluazinam. Active ingredients of the bactericidal composition are formed by fluazinam (A) and eugenol (B). The weight ratio of A to that of B is from 1:50 to 100:1. The composition has a significant synergistic effect and a high control effect. The composition is adapted for preventing and curing various diseases of fruits and vegetables, and is particularly adapted for preventing and curing pepper | 12-10-2015 |
20150353467 | 3,4-DIAMINOPYRIDINE TARTRATE AND PHOSPHATE, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to 3,4-diaminopyridine salts, pharmaceutical compositions containing at least one of said salts and uses thereof for the treatment of botulism, myasthenia, myasthenic syndromes or fatigue. | 12-10-2015 |
20160008336 | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY | 01-14-2016 |
20160038451 | FORMULATIONS AND USES OF RETINOIC ACID RECEPTOR SELECTIVE AGONISTS - The invention provides retinoic acid receptor (RAR) selective agonists and formulations thereof for the treatment of disease or for inducing a medically beneficial effect. | 02-11-2016 |
20160052886 | DERIVATIVES OF NICOTINIC ACID N-OXIDE, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF ENZYME 3-HYDROXYANTHRANILATE-3, 4-DIOXYGENASE - A derivative of nicotinic acid N-oxide is described having formula (I): that acts as inhibitor of enzyme 3-hydroxyanthranilate-3,4-dioxygenase (3HAO), and is thus able to reduce QUIN biosynthesis in vivo under excitotoxic or pathological conditions, said compound being at the same time also chemically stable towards auto-oxidation. | 02-25-2016 |
20160058743 | METHODS FOR TREATING SENSORIMOTOR IMPAIRMENTS ASSOCIATED WITH CERTAIN TYPES OF STROKE USING AMINOPYRIDINES - Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with stroke-related impairments, in particular, in patients with sensorimotor impairments resulting from certain types of stroke. | 03-03-2016 |
20160067230 | METHODS FOR TREATING AN IMPAIRMENT IN GAIT AND/OR BALANCE IN PATIENTS WITH MULTIPLE SCLEROSIS USING AN AMINOPYRIDINE - Disclosed herein is use of one or more aminopyridines in methods and compositions for treatment of impairments in gait or balance in patients with multiple sclerosis. | 03-10-2016 |
20160067232 | METHODS FOR TREATING A STROKE-RELATED SENSORIMOTOR IMPAIRMENT USING AMINOPYRIDINES - Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with a stroke-related impairment, in particular, in patients with a stroke-related sensorimotor impairment. | 03-10-2016 |
20160081992 | Sustained Release Aminopyridine Composition - A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases. | 03-24-2016 |
20160101089 | NOVEL PHARMACEUTICAL SALTS AND POLYMORPHS OF A FACTOR XA INHIBITOR - The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. | 04-14-2016 |
20160168108 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | 06-16-2016 |
20160175275 | METHOD OF TREATING OR PREVENTING RAS-MEDIATED DISEASES | 06-23-2016 |
20160175294 | Sustained Release Aminopyridine Composition | 06-23-2016 |
20160184286 | DURABLE TREATMENT WITH 4-AMINOPYRIDINE IN PATIENTS WITH DEMYELINATION - Disclosed herein are methods and compositions related to the durable use of aminopyridines, such as 4-aminopyridine, to improve impairments of patients with a demyelinating condition, such as MS. | 06-30-2016 |
20160199358 | METHODS OF USING SUSTAINED RELEASE AMINOPYRIDINE COMPOSITIONS | 07-14-2016 |
20170233343 | PRODRUG | 08-17-2017 |